Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Palisade Bio ( (PALI) ) has provided an announcement.
On March 30, 2026, Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc., doing business as Iterative Health, to support and accelerate patient enrollment for an anticipated Phase 2 study of its ulcerative colitis candidate PALI-2108. This collaboration is intended to streamline recruitment of moderate to severe ulcerative colitis patients, potentially shortening timelines for the trial and advancing Palisade Bio’s clinical development plans.
On March 27, 2026, Palisade Bio issued and sold 1,536,885 shares of its common stock to an affiliate of Iterative Health for $3.0 million, priced at $1.952 per share, in a private transaction exempt from registration under U.S. securities laws. The equity investment from Iterative Health’s affiliate both funds upcoming clinical work and deepens the strategic relationship between the two companies around the development of PALI-2108.
The most recent analyst rating on (PALI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and sustained cash burn). Technical indicators are modestly positive and provide some support, but valuation remains difficult to justify with negative earnings and no dividend yield information.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Palisade Bio, Inc. is a biopharmaceutical company focused on developing therapies for gastrointestinal diseases, including treatments for patients with moderate to severe ulcerative colitis. Its pipeline includes PALI-2108, an investigational drug candidate aimed at addressing unmet medical needs in inflammatory bowel disease and improving outcomes in this specialized GI market.
Average Trading Volume: 4,413,367
Technical Sentiment Signal: Sell
Current Market Cap: $311.9M
See more data about PALI stock on TipRanks’ Stock Analysis page.